TERRY WHITEHEAD: Open Payments
NPI 1386166510 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$723 in 28 payments from 11 companies in 2025. Trend: 2023 $329 · 2024 $918 · 2025 $723
Food & beverage: $723
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 6 | $186 |
| ABBVIE INC. | 7 | $154 |
| Novartis Pharmaceuticals Corporation | 4 | $93 |
| Lundbeck LLC | 2 | $64 |
| Janssen Biotech, Inc. | 2 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| SK Life Science, Inc. | 1 | $31 |
| Genentech USA, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $24 |
Products named: VYVGART HYTRULO, KESIMPTA, QULIPTA, VYEPTI, UBRELVY, CREXONT, INGREZZA, VYALEV.
Industry payments across AL — which companies pay providers there.
